

# Pharmaceutical Benefits Scheme (PBS) Listings

## 1 March 2026

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 March 2026**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

### **Diabetic macular oedema (DMO); subfoveal choroidal neovascularisation (CNV)**

Aflibercept (8 mg/0.07 mL injection, 0.07 mL syringe) (Eylea®) is now listed on the PBS for the treatment of DMO and for CNV due to age-related macular degeneration (AMD). Authority applications for initial treatment of DMO can be made using the Online PBS Authorities system or by telephone. Authority applications for initial treatment of CNV due to AMD can be made using the Online PBS Authorities system or in writing. Prescriptions for continuing treatment of DMO and CNV due to AMD are Authority required (STREAMLINED).

### **Severe chronic plaque psoriasis**

Bimekizumab (320 mg/2 mL injection, 2 mL pen devices) (Bimzelx®) is now listed on the PBS for the treatment of severe chronic plaque psoriasis. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or in writing.

### **Severe active rheumatoid arthritis; severe psoriatic arthritis; ankylosing spondylitis; severe chronic plaque psoriasis; severe active juvenile idiopathic arthritis**

Etanercept (50 mg/mL injection, 4 x 1 mL syringes) (Nepexto®) is a new biosimilar now listed on the PBS for the treatment of severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis and severe active juvenile idiopathic arthritis.

### **Generalised myasthenia gravis (gMG)**

Ravulizumab (300 mg/3 mL injection, 3 mL vial; 1.1 g/11 mL injection, 11 mL vial) (Ultomiris®) is now listed on the PBS for the treatment of gMG. Authority applications for the treatment of acute severe gMG, bridging therapy, and for initial, continuing and grandfather treatments of treatment refractory gMG can be made using the Online PBS Authorities system or in writing.

### **Spinal muscular atrophy (SMA)**

Nusinersen (12 mg/5 mL intrathecal injection, 5 mL vial) (Spinraza®) and risdiplam (750 microgram/mL powder for oral liquid, 80 mL) (Evrysdi®) have had an update to their restrictions. Authority applications for initial treatment can be made using the Online PBS Authorities system or in writing. Authority applications for continuing or change of treatment can be made using the Online PBS Authorities system or by telephone.

### **Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)**

Glofitamab (2.5 mg/2.5 mL injection, 2.5 mL vial; 10 mg/10 mL injection, 10 mL vial) (Columvi®) is now listed on the PBS for the treatment of DLBCL. Authority applications for initial treatment (Cycle 1, Day 8 and Day 15), grandfather and continuing treatments (Cycle 2-12) can be made using the Online PBS Authorities system or by telephone.

Note: As the Prescribed quantity field in the Online PBS Authorities system cannot contain decimal places, ensure that the prescribed quantity is requested in micrograms (mcg) not milligrams (mg) when requesting authority approval for glofitamab.

## **Schizophrenia**

Aripiprazole (300 mg modified release injection [1 chamber] (&) inert substance diluent [1.2 mL chamber], 1 dual chamber syringe; 400 mg modified release injection [1 chamber] (&) inert substance diluent [1.6 mL chamber], 1 dual chamber syringe) (Abilify Maintena®) is now listed on the PBS for the treatment of schizophrenia. Prescriptions for treatment are Authority required (STREAMLINED).

## **Osteoporosis; established osteoporosis; giant cell tumour of bone; bone metastases**

Denosumab (60 mg/mL injection, 1 mL syringe) (Stoboclo®) (120 mg/1.7 mL injection, 1.7 mL vial) (Osenvelt®) has two new biosimilars now listed on the PBS for the treatment of osteoporosis, established osteoporosis, giant cell tumour of bone and bone metastases. Prescriptions for treatments are Authority required (STREAMLINED).

## **Chronic sialorrhoea**

IncobotulinumtoxinA (100 units injection, 1 vial) (Xeomin®) is now listed on the PBS for the treatment of chronic sialorrhoea. Prescriptions for treatment are Authority required (STREAMLINED).

## **Immunotherapy sensitive advanced or metastatic cancer**

Nivolumab + ipilimumab (nivolumab 40 mg/4 mL injection, 4 mL vial; 100 mg/10 mL injection, 10 mL vial) (Opdivo®) (ipilimumab 50 mg/10 mL injection, 10 mL vial; 200 mg/40 mL injection, 40 mL vial) (Yervoy®) have new listings on the PBS for the treatment of immunotherapy sensitive advanced or metastatic cancer. A number of indications have been consolidated into the new listings. As a result, a number of item codes have been deleted, and new prescriptions will be needed from 1 March 2026. Prescriptions for treatments are Authority required (STREAMLINED).

## **Prevention of venous thromboembolism (VTE); treatment of venous thrombosis; prevention of extracorporeal thrombosis during haemodialysis; treatment of acute ST-segment elevation myocardial infarction (STEMI), non-STEMI and unstable angina**

Enoxaparin (enoxaparin sodium 20 mg/0.2 mL injection, 10 x 0.2 mL syringes; enoxaparin sodium 40 mg/0.4 mL injection, 10 x 0.4 mL syringes; enoxaparin sodium 60 mg/0.6 mL injection, 10 x 0.6 mL syringes; enoxaparin sodium 80 mg/0.8 mL injection, 10 x 0.8 mL syringes; enoxaparin sodium 100 mg/mL injection, 10 x 1 mL syringes; enoxaparin sodium 120 mg/0.8 mL injection, 10 x 0.8 mL syringes; enoxaparin sodium 150 mg/mL injection, 10 x 1 mL syringes) (Enoxaject®) is a new biosimilar now listed on the PBS as a restricted benefit.

## **Diabetes mellitus type 2**

Pioglitazone (15 mg tablet; 30 mg tablet; 45 mg tablet) (Actos®) has a new pack size of 30 now listed on the PBS as a restricted benefit.

## **Additions to PBS listings for 60-day prescriptions**

The following medicines are now available for 60-day prescriptions on the PBS:

Beclometasone + formoterol + glycopyrronium (beclomethasone dipropionate 100 microgram/actuation + formoterol fumarate dihydrate 6 microgram/actuation + glycopyrronium 10 microgram/actuation inhalation, 120 actuations; beclometasone dipropionate 200 microgram/actuation + formoterol fumarate dihydrate 6 microgram/actuation + glycopyrronium 10 microgram/actuation inhalation, 120 actuations) (Trimbow®) for the treatment of severe asthma. Prescriptions for treatment are Authority required (STREAMLINED).

Budesonide + formoterol (budesonide 200 microgram/actuation + formoterol fumarate dihydrate 6 microgram/actuation powder for inhalation, 60 actuations) (Bufomix Easyhaler 200/6®) for the treatment of asthma. Prescriptions for treatment are Authority required (STREAMLINED).

Dapagliflozin (10 mg tablet) (Forxiga®) and empagliflozin (10 mg tablet) (Jardiance®) for the treatment of chronic kidney disease. Prescriptions for treatment are Authority required (STREAMLINED).

Ivabradine (5 mg tablet; 7.5 mg tablet) (several brands) for the treatment of chronic heart failure. Prescriptions for treatment are Authority required (STREAMLINED).

Opicapone (50 mg capsule) (Ongentys®) for the treatment of Parkinson's disease. It is listed as a restricted benefit.

Propylene glycol (0.6% eye drops, 10 mL) (Systane Balance®) for the treatment of severe dry eye syndrome. It is listed as a restricted benefit.

### **HIV infection**

TENOFOVIR DISOPROXIL + EMTRICITABINE + EFAVIRENZ (tenofovir disoproxil fumarate 300mg + emtricitabine 200 mg + efavirenz 600 mg tablet) (Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 600 mg/200 mg/300 mg (Camber, USA)®) for the treatment of HIV infection is now listed on the PBS for the current supply shortage under Section 19A. Prescriptions for treatment are Authority required (STREAMLINED).

### **Schistosomiasis**

Praziquantel (600 mg tablet) (Distocide (Korea)®) for the treatment of schistosomiasis is now listed on the PBS for the current supply shortage under Section 19A. Prescriptions for treatment are Authority required (STREAMLINED).

### **1 March 2026 delisted PBS listings**

#### **Precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL)**

Blinatumomab (38.5 microgram injection [1 vial] (& inert substance solution [10 mL vial], 1 pack) (Blincyto®) no longer has a listing for Grandfather arrangements.

#### **Severe psoriatic arthritis**

Risankizumab (150 mg/mL injection, 1 mL pen device) (Skyrizi®) no longer has a listing for Grandfather arrangements.

#### **Endogenous Cushing's syndrome**

Osilodrostat (1 mg tablet; 5 mg tablet) (Isturisa®) no longer has a listing for Grandfather arrangements.

### **PBS Authorities – Changes from 1 March 2026**

We understand having access to PBS-subsidised medicines can be critical to patient care. That's why Services Australia and the Department of Health, Disability and Ageing are continuing to work together to increase the number of PBS medicines that can be requested and approved using the Online PBS Authorities system (the system).

From 1 March 2026, you will be able to use the system to apply for authority approval and provide evidence digitally for the following medicines. These changes will make it easier for you to request authority approval for these medicines from Services Australia. You will no longer need to submit the written authority application form, details of the proposed prescriptions and test results for certain medicines and treatment phases.

#### **Treatment of atypical haemolytic uraemic syndrome (aHUS)**

Authority applications for initial, switching, grandfather (ravulizumab only), recommencement and continuing treatments with eculizumab or ravulizumab for the treatment of aHUS can now be made using the Online PBS Authorities system or in writing.

#### **Treatment of systemic lupus erythematosus**

Authority applications for initial treatment with anifrolumab for the treatment of systemic lupus erythematosus can now be made in real-time using the Online PBS Authorities system or in writing. Authority applications for continuing treatment and recommencement of treatment (within 12 months of a treatment break) can be made using the Online PBS Authorities system or by telephone.

## Treatment of acute lymphoblastic leukaemia

Authority applications for initial treatment with blinatumomab, dasatinib, inotuzumab ozogamicin and ponatinib for the treatment of acute lymphoblastic leukaemia can now be made using the Online PBS Authorities system or in writing. Authority applications for initial treatment with imatinib can be made using the Online PBS Authorities system or by telephone. Authority applications for continuing treatment can be made using the Online PBS Authorities system or by telephone.

### IMPORTANT INFORMATION



#### **New Adult Crohn's Disease Activity Index Form Now Available**

The newly published Adult Crohn's Disease Activity Index (CDAI) Form is now available on the Services Australia website. This is a standalone CDAI calculation sheet that can be used when requesting an authority via the Online PBS Authorities system.



#### **Integrated clinical and prescribing software**

Several clinical and prescribing software developers now have products available for use to request PBS authority approval directly from your clinical and prescribing software. This means you can request PBS authority approval as part of generating the authority prescription rather than calling, applying in writing or self-serving through the PBS Authorities tile in HPOS. For more information, speak with your software provider.



#### **Submitting Pharmaceutical Benefits Scheme (PBS) Written Applications through Health Professional Online Services (HPOS) form upload**

When submitting PBS authority forms through HPOS form upload, it is important to select the correct Form Category. For PBS patients, select PBS Authorities. For DVA patients, select RPBS Authorities. Remember that only yourself or your delegate/s are authorised to upload PBS and RPBS Authority applications.

Make sure you've:

- linked your prescriber number to your Provider Digital Access (PRODA) account for HPOS; and
- Set up your delegations in HPOS.

Visit [servicesaustralia.gov.au/HPOS](https://servicesaustralia.gov.au/HPOS) for more information on how to Link your Health Identifiers to HPOS and Manage delegations.



#### **PBS Authorities items criteria**

Under the PBS, medicines are made available based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). Patients must meet the set criteria to be eligible for PBS subsidised medicines. Services Australia are unable to provide approval for an Authority Required medication where a patient does not meet the criteria established by PBAC.

If you have concerns or questions about the eligibility criteria set by the PBAC, you can contact the Department of Health, Disability and Ageing by email at [pbs@health.gov.au](mailto:pbs@health.gov.au).

## REMINDERS



### **PBS Authorities – written authority application forms**

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval. Search the Services Australia website to access the most recent forms.



### **Correct PBS item code**

When prescribing PBS medicines via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.



### **Ensuring you are providing accurate data**

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.



For more information about the Online PBS Authorities system visit [www.servicesaustralia.gov.au/hppbsauthorities](http://www.servicesaustralia.gov.au/hppbsauthorities)

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>

Visit [servicesaustralia.gov.au/hpwrittenauthoritydrugs](http://servicesaustralia.gov.au/hpwrittenauthoritydrugs) on the Services Australia website to find the most up to date authority application form for each drug, program or condition.